Cargando…
Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
BACKGROUND: Programmed death-ligand 1 (PD-L1) positivity is associated with poor prognosis in renal cell carcinoma (RCC). Because the prognostic impact and effect of confounding factors are less known, we investigated the prognostic significance of PD-L1 expression in Japanese patients with recurren...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520884/ https://www.ncbi.nlm.nih.gov/pubmed/34291367 http://dx.doi.org/10.1007/s10147-021-01993-x |
_version_ | 1784584775733870592 |
---|---|
author | Uemura, Motohide Nakaigawa, Noboru Sassa, Naoto Tatsugami, Katsunori Harada, Kenichi Yamasaki, Toshinari Matsubara, Nobuaki Yoshimoto, Takuya Nakagawa, Yuki Fukuyama, Tamaki Oya, Mototsugu Shinohara, Nobuo Uemura, Hirotsugu Tsuzuki, Toyonori |
author_facet | Uemura, Motohide Nakaigawa, Noboru Sassa, Naoto Tatsugami, Katsunori Harada, Kenichi Yamasaki, Toshinari Matsubara, Nobuaki Yoshimoto, Takuya Nakagawa, Yuki Fukuyama, Tamaki Oya, Mototsugu Shinohara, Nobuo Uemura, Hirotsugu Tsuzuki, Toyonori |
author_sort | Uemura, Motohide |
collection | PubMed |
description | BACKGROUND: Programmed death-ligand 1 (PD-L1) positivity is associated with poor prognosis in renal cell carcinoma (RCC). Because the prognostic impact and effect of confounding factors are less known, we investigated the prognostic significance of PD-L1 expression in Japanese patients with recurrent/metastatic RCC who started systemic therapy in 2010–2015. METHODS: This multicenter, retrospective study recruited patients from 29 Japanese study sites who had prior systemic therapy for RCC (November 2018 to April 2019) and stored formalin-fixed paraffin-embedded primary lesion samples. The primary outcome was overall survival (OS) by PD-L1 expression. Secondary outcomes included OS in subgroups and duration of first- and second-line therapies by PD-L1 expression. OS distributions were estimated using Kaplan–Meier methodology. RESULTS: PD-L1 expression (on immune cells [IC] ≥ 1%) was observed in 315/770 (40.9%) patients. PD-L1 positivity was more prevalent in patients with poor risk per both Memorial Sloan Kettering Cancer Center [MSKCC] and International Metastatic RCC Database Consortium, and high-risk pathological features (higher clinical stage, nuclear grade and sarcomatoid features). Median OS for PD-L1–positive patients was 30.9 months (95% CI 25.5–35.7) versus 37.5 months (95% CI 34.0–42.6) for PD-L1–negative patients (HR 1.04 [90% CI 0.89–1.22, p = 0.65]; stratified by MSKCC risk and liver metastases). Propensity score weight (PSW)-adjusted OS was similar between PD-L1–positive and –negative patients (median 34.4 versus 31.5 months; estimated PSW-adjusted HR 0.986). CONCLUSIONS: This study suggests PD-L1 status was not an independent prognostic factor in recurrent/metastatic RCC during the study period because PD-L1 positivity was associated with poor prognostic factors, especially MSKCC risk status. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10147-021-01993-x. |
format | Online Article Text |
id | pubmed-8520884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-85208842021-10-29 Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma Uemura, Motohide Nakaigawa, Noboru Sassa, Naoto Tatsugami, Katsunori Harada, Kenichi Yamasaki, Toshinari Matsubara, Nobuaki Yoshimoto, Takuya Nakagawa, Yuki Fukuyama, Tamaki Oya, Mototsugu Shinohara, Nobuo Uemura, Hirotsugu Tsuzuki, Toyonori Int J Clin Oncol Original Article BACKGROUND: Programmed death-ligand 1 (PD-L1) positivity is associated with poor prognosis in renal cell carcinoma (RCC). Because the prognostic impact and effect of confounding factors are less known, we investigated the prognostic significance of PD-L1 expression in Japanese patients with recurrent/metastatic RCC who started systemic therapy in 2010–2015. METHODS: This multicenter, retrospective study recruited patients from 29 Japanese study sites who had prior systemic therapy for RCC (November 2018 to April 2019) and stored formalin-fixed paraffin-embedded primary lesion samples. The primary outcome was overall survival (OS) by PD-L1 expression. Secondary outcomes included OS in subgroups and duration of first- and second-line therapies by PD-L1 expression. OS distributions were estimated using Kaplan–Meier methodology. RESULTS: PD-L1 expression (on immune cells [IC] ≥ 1%) was observed in 315/770 (40.9%) patients. PD-L1 positivity was more prevalent in patients with poor risk per both Memorial Sloan Kettering Cancer Center [MSKCC] and International Metastatic RCC Database Consortium, and high-risk pathological features (higher clinical stage, nuclear grade and sarcomatoid features). Median OS for PD-L1–positive patients was 30.9 months (95% CI 25.5–35.7) versus 37.5 months (95% CI 34.0–42.6) for PD-L1–negative patients (HR 1.04 [90% CI 0.89–1.22, p = 0.65]; stratified by MSKCC risk and liver metastases). Propensity score weight (PSW)-adjusted OS was similar between PD-L1–positive and –negative patients (median 34.4 versus 31.5 months; estimated PSW-adjusted HR 0.986). CONCLUSIONS: This study suggests PD-L1 status was not an independent prognostic factor in recurrent/metastatic RCC during the study period because PD-L1 positivity was associated with poor prognostic factors, especially MSKCC risk status. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10147-021-01993-x. Springer Singapore 2021-07-21 2021 /pmc/articles/PMC8520884/ /pubmed/34291367 http://dx.doi.org/10.1007/s10147-021-01993-x Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Uemura, Motohide Nakaigawa, Noboru Sassa, Naoto Tatsugami, Katsunori Harada, Kenichi Yamasaki, Toshinari Matsubara, Nobuaki Yoshimoto, Takuya Nakagawa, Yuki Fukuyama, Tamaki Oya, Mototsugu Shinohara, Nobuo Uemura, Hirotsugu Tsuzuki, Toyonori Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma |
title | Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma |
title_full | Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma |
title_fullStr | Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma |
title_full_unstemmed | Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma |
title_short | Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma |
title_sort | prognostic value of programmed death-ligand 1 status in japanese patients with renal cell carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520884/ https://www.ncbi.nlm.nih.gov/pubmed/34291367 http://dx.doi.org/10.1007/s10147-021-01993-x |
work_keys_str_mv | AT uemuramotohide prognosticvalueofprogrammeddeathligand1statusinjapanesepatientswithrenalcellcarcinoma AT nakaigawanoboru prognosticvalueofprogrammeddeathligand1statusinjapanesepatientswithrenalcellcarcinoma AT sassanaoto prognosticvalueofprogrammeddeathligand1statusinjapanesepatientswithrenalcellcarcinoma AT tatsugamikatsunori prognosticvalueofprogrammeddeathligand1statusinjapanesepatientswithrenalcellcarcinoma AT haradakenichi prognosticvalueofprogrammeddeathligand1statusinjapanesepatientswithrenalcellcarcinoma AT yamasakitoshinari prognosticvalueofprogrammeddeathligand1statusinjapanesepatientswithrenalcellcarcinoma AT matsubaranobuaki prognosticvalueofprogrammeddeathligand1statusinjapanesepatientswithrenalcellcarcinoma AT yoshimototakuya prognosticvalueofprogrammeddeathligand1statusinjapanesepatientswithrenalcellcarcinoma AT nakagawayuki prognosticvalueofprogrammeddeathligand1statusinjapanesepatientswithrenalcellcarcinoma AT fukuyamatamaki prognosticvalueofprogrammeddeathligand1statusinjapanesepatientswithrenalcellcarcinoma AT oyamototsugu prognosticvalueofprogrammeddeathligand1statusinjapanesepatientswithrenalcellcarcinoma AT shinoharanobuo prognosticvalueofprogrammeddeathligand1statusinjapanesepatientswithrenalcellcarcinoma AT uemurahirotsugu prognosticvalueofprogrammeddeathligand1statusinjapanesepatientswithrenalcellcarcinoma AT tsuzukitoyonori prognosticvalueofprogrammeddeathligand1statusinjapanesepatientswithrenalcellcarcinoma |